Medtronic will report its Q2 results on Tuesday, with analysts expecting 3.8% revenue growth to $8.86 billion and GAAP EPS of $0.95. Forecasts cite improving sentiment, governance changes and margin expansion potential. Investors will track updates on renal denervation, robotics and other pipeline programs as analysts say the company looks confidently ready for its US robotics push.